Results 231 to 240 of about 70,621 (279)

Trastuzumab

BioDrugs, 1999
Trastuzumab is a recombinant humanised monoclonal antibody specific for the growth factor receptor p185(HER2) (HER2) which is overexpressed in 25 to 30% of breast cancer tumours. The drug inhibits the growth of human breast cancer cells overexpressing HER2 in vitro and in vivo.
C M, Perry, L R, Wiseman
openaire   +2 more sources

Trastuzumab

Reactions Weekly, 2019
  +9 more sources

Trastuzumab

Reactions Weekly, 2009
Edith A, Perez, Frances M, Palmieri, Shelly M, Brock   +2 more
openaire   +3 more sources

Trastuzumab/trastuzumab emtansine

Reactions Weekly, 2023
openaire   +1 more source

Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

Ca-A Cancer Journal for Clinicians, 2022
Paolo Tarantino, Roberto Carmagnani Pestana, Shanu Modi   +2 more
exaly  

Anastrozole/trastuzumab/trastuzumab emtansine

Reactions Weekly, 2022
openaire   +1 more source

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

New England Journal of Medicine, 2022
Javier Cortes, Martina Uttenreuther-Fischer, Seock-Ah Im   +2 more
exaly  

Pertuzumab/trastuzumab/trastuzumab emtansine

Reactions Weekly, 2021
openaire   +1 more source

Trastuzumab-emtansine/trastuzumab

Reactions Weekly, 2020
openaire   +1 more source

Poziotinib/trastuzumab-deruxtecan/trastuzumab-emtansine

Reactions Weekly, 2022
openaire   +1 more source